Vincerx Pharma
VINC

Delisted

VINC was delisted on the 16th of April, 2025.

Back to rankings

About: Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.

Employees: 13

Healthcare Biotechnology

Financial journalist opinion

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger.

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has entered into a non-binding letter of intent (“LOI”) with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx.

Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated.

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

Vincerx Pharma, Inc. Announces Reverse Stock Split

Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025 Vincerx's Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025

Vincerx Pharma, Inc. Announces Reverse Stock Split

VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma, Inc. (NasdaqCM: VINC) and Oqory, Inc. Pursuant to the terms of the agreement, at the closing of the transaction, Vincerx equity holders will hold about 5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger.

VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC

VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Vincerx Pharma, Inc. (NASDAQ: VINC) and Oqory, Inc. is fair to Vincerx shareholders. Upon completion of the proposed transaction, Vincerx equity holders will hold about 5% of the combined company. Halper Sadeh encourages Vincerx shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.

VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders

Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Oqory merge with Vincerx and Oqory equity holders will own approximately 95% of the combined en.

Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company's pipeline

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943

Also Exploring Strategic Alternatives to Complement Fundraising Efforts Also Exploring Strategic Alternatives to Complement Fundraising Efforts

Vincerx Pharma to Implement Cost-Controls to Support Advancing Phase 1 Study of VIP943

See News Rankings

Charts implemented using Lightweight Charts™